So far, 40 papers about Semenza have been published on Pubpeer, a well-known academic website. The time is from 200 1 to 20 18, and the span is 18. The problem is that one picture is multi-purpose or the picture PS, and a few articles are suspected to have ethical problems. Among them, more than half of the papers involved breast cancer, coronary artery abnormality, hypertension, polycythemia and other diseases.
Fortunately, Semenza's two "key works" published in the Nobel Prize official website were not copied. Insiders said, "Semenza's most important contribution is his series of work in discovering hypoxia-inducible factor HIF- 1 in the 1990s, and these papers that were exposed to problems were not among them."
The insider also said, "If this had happened two years earlier, Semenza probably wouldn't have won the Nobel Prize. But even if it is exposed now, there is a high probability that his Nobel Prize will not be revoked. After all, the Nobel Prize was awarded to completely wrong research and wrong conclusions in history, but there is no precedent for revocation. "
Extended data:
Introduction to Greg Semenza
Semenza 1956 was born in new york and is 64 years old. From 65438 to 0999, he became a full-time professor at Johns Hopkins University. Since 2003, he has been the director of the vascular research project of the Institute of Cell Engineering.
In 20 19, Semenza and two other scientists, ratcliffe and Lin Kai, won the Nobel Prize in Physiology or Medicine for their "discovery in the mechanism of cell perception and adaptation to oxygen changes".
In the early 1990s, hypoxia inducible factor HIF- 1 was discovered in Semenza laboratory, and it was purified and cloned in 1995. Since then, ratcliffe and Lin Kai have discovered the degradation mechanism of HIF.
In recent years, Semenza's main research direction is the relationship between HIF- 1 and tumor, ischemic heart disease, coronary heart disease, chronic lung disease and other diseases.
In an interview with the media, he once said that he attached great importance to the "transformation of scientific research results" and hoped that his research results would go clinical and benefit more patients.
Wang Shun Nobel Prize winner Semenza is suspected of falsifying his thesis.